{"article_title": "How Durata Plans To Market Its Expensive New Antibiotic", "article_keywords": ["durata", "expensive", "antibiotic", "plans", "market"], "article_url": "http://www.forbes.com/sites/wendydiller/2014/06/05/how-durata-plans-to-market-its-expensive-new-antibiotic/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "Wendy Diller", "og": {"site_name": "Forbes", "description": "FDA\u2019s approval on May 23 of Durata Therapeutics Inc.\u2019s antibiotic Dalvance (dalbavancin) underscores the potential and also the challenges life science companies face in grappling with new payment and delivery reform models, some driven by the Affordable Care Act (ACA), but also independent of it. The drug is indicated for [...]", "title": "How Durata Plans To Market Its Expensive New Antibiotic", "url": "http://www.forbes.com/sites/wendydiller/2014/06/05/how-durata-plans-to-market-its-expensive-new-antibiotic/", "image": "http://blogs-images.forbes.com/wendydiller/files/2014/06/Duratadurata.jpg", "updated_time": "2014-06-16T10:49:19-04:00", "type": "article"}, "twitter": {"description": "FDA\u2019s approval on May 23 of Durata Therapeutics Inc.\u2019s antibiotic Dalvance (dalbavancin) underscores the potential and also the challenges life science companies face in grappling with new payment and delivery reform models, some driven by the Affordable Care Act (ACA), but also independent of it. The drug is indicated for [...]", "title": "How Durata Plans To Market Its Expensive New Antibiotic", "image": "http://blogs-images.forbes.com/wendydiller/files/2014/06/Duratadurata.jpg", "creator": "@@wendydiller", "site": "@forbes", "card": "summary_large_image"}, "description": "FDA\u2019s approval on May 23 of Durata Therapeutics Inc.\u2019s antibiotic Dalvance (dalbavancin) underscores the potential and also the challenges life science companies face in grappling with new payment and delivery reform models, some driven by the Affordable Care Act (ACA), but also independent of it. The drug is indicated for [...]", "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Healthcare  Fiscal,Healthcare Innovation,Pharma and Health,Powering Productivity,Healthcare &amp; Fiscal,Pharma &amp; Healthcare,antibiotics,cellulitis,complex skin infections,Durata,Medicare,MRSA,reimbursement", "article": {"publisher": "https://www.facebook.com/forbes", "section_url": "http://www.forbes.com/healthcare-innovation", "section": "Healthcare Innovation", "modified": "2014-06-16", "published": "2014-06-05", "id": "blogAndPostId/blog/post/3144-6"}, "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "news_keywords": "Healthcare  Fiscal,Healthcare Innovation,Pharma and Health,Powering Productivity,Healthcare &amp; Fiscal,Pharma &amp; Healthcare,antibiotics,cellulitis,complex skin infections,Durata,Medicare,MRSA,reimbursement"}, "_id": "\"57477af46914bd0286fd7e76\"", "article_summary": ""}